CRISM Therapeutics Corp (CRTX) NPV

Sell:8.00pBuy:9.00pNo change

Prices delayed by at least 15 minutes
Sell:8.00p
Buy:9.00p
Change:No change
Prices delayed by at least 15 minutes
Sell:8.00p
Buy:9.00p
Change:No change
Prices delayed by at least 15 minutes

Company Information

About this company

CRISM Therapeutics Corporation, formerly Amur Minerals Corporation, is a British Virgin Islands-based pharmaceutical company. The Company has developed a drug delivery technology, ChemoSeed, to improve the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy. Its lead product, ChemoSeed, is a polymer the size of a grain of rice, administering irinotecan, a generic drug approved to treat brain cancer and can be implanted directly into a tumor or the resection margin following the removal of a tumor, thereby ensuring that effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. It seeks to use ChemoSeed to treat high grade gliomas, a brain tumor with no satisfactory treatment. The Company also offers formulation and consultancy services. It provides assistance and services to improve the bioavailability of poorly soluble drugs. It offers remixers and extruders of various sizes.

Key people

Robin J. Young
Chief Executive Officer, Executive Director
Robert W. Schafer
Independent Non-Executive Chairman of the Board
Thomas Edward Bowens
Non-Executive Independent Director
Paul Terence Gazzard
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    CRTX
  • Location
    Virgin Islands (British)
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    VGG042401262
  • Market cap
    £2.78m
  • Employees
    4
  • Shares in issue
    32.68m
  • Exchange
    London Stock Exchange (LON)
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.